Global Biosimilar Market Trends, Opportunities and 2018 Forecasts Analysis adds “Global Biosimilar Market Trends & Opportunities: 2015 Edition“ report to its research store.


Dallas, TX -- (SBWire) -- 01/23/2015 --The report titled "Global Biosimilar Market: Trends & Opportunities (2015 Edition)" analyzes the global biologics market, with exhaustive discussion on demand of Biosimilars with increase in patent expiry of innovator drugs. The key market challenges recognized by the analysts and the major trends biosimilar market are presented in the report. Further, key manufacturers of Biosimilars like Sandoz, Teva, Hospira and Dr. Reddy's Lab are profiled in the report.

Product Coverage

- Recombinant Glycosylated Biosimilars (EPO,mAb,Follitropin)
- Humira, Enbrel, Remicade, Herceptin
- Recombinant Non-Glycosylated Biosimilars (Insulin,G-csf,Interferons,hGh)

Company Coverage

- Sandoz(Novartis)
- Hospira
- Teva
- Dr. Reddy's Lab

Complete report available

Rising budgetary pressures to reduce healthcare expenditures, patent expiries of blockbuster drugs, growing demand for cost-effective alternatives, increasing aging population, conductive government initiatives and rising incidences of various diseases are significant factors that are responsible for the growth of global biosimilar market (2013 to 2018). On the other hand stringent regulatory environment in some countries, high manufacturing complexities, costs, and presence of low priced generic drugs and high-entry barriers are considered to hinder the market growth. Emerging pharmaceutical market and less stringent government regulatory frameworks in few countries can provides some of the major opportunities for biosimilars market. In addition, increased collaboration between manufacturing companies and outsourcing of biosimilar products are key trends for biosimilars market.

Order a copy of this research report

The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. Globally there are 280 biosimilars in pipeline and their clinical trials are increasing at a rate of 20% annually.

This report provides an in-depth analysis of the growing Biosimilar Market with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall Biosimilars industry has also been forecasted for the period 2014-18, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Major points from Table of Contents are listed below:

List of Tables and Figures

Figure 1 : Original And Biosimilar Medicine
Figure 2 : Original And Biosimilar Medicine
Figure 3: A stir tank bioreactor
Figure 4: Biosimilars Omnitrope and Accofil
Table 1: List of Biosimilars approved by EMA
Figure 5: Global Biosimilar Market (2009-2013)-sales-U.S$ Billion
Figure 6: Biosimilar Products Market Share (2013)
Figure 7: Global Biosimilar Market Sales (2014-2018) in U.S$ Billion
Figure 8: Global biosimilar market share by geography (2013)
Figure 9: Biosimilar uptake across countries in Europe in 2013
Figure 10: Biosimilar Market - Recombinant Glycosylated Products – Sales (2009-2013) - US$ Billion
Figure 11: Biosimilar Market - Recombinant Glycosylated Products – Sales (2014-2018) - US$ Billion

Explore more reports on Pharmaceuticals Industry:

US Pharmacy Benefit Management (PBM) Industry Report: 2014 Edition ( The PBM providers control drug spending and utilization by virtue of their advanced tools and techniques, encouraging use of generics and other lower-cost medications. In the US, there are some independent PBM's while some are owned by managed care organizations and retail pharmacies. Today, the PBM industry has become more determined through a series of mergers and acquisitions.

Global Combined Hormonal Contraceptives (CHC) Market: Trends and Opportunities (2014-19) ( Combined Hormonal Contraceptives (CHC) is widely being used as an effective and reversible birth control method. Mainly used for preventing pregnancies but sometimes also used for treating acne vulgaris, endometriosis, polycystic ovarian syndrome and irregular menstrual flow, CHC works by preventing ovulation i.e. release of egg from ovaries. The hormones are provided in the combined pill, patch or ring.

About MarketReportsOnline
MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Contact Us:
Ritesh Tiwari
Corporate Office
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
Tel: 888-391-5441

Media Relations Contact

Ritesh Tiwari

View this press release online at: